+

WO1992016181A2 - Procede favorisant la reparation et la regeneration tissulaires - Google Patents

Procede favorisant la reparation et la regeneration tissulaires Download PDF

Info

Publication number
WO1992016181A2
WO1992016181A2 PCT/US1992/002043 US9202043W WO9216181A2 WO 1992016181 A2 WO1992016181 A2 WO 1992016181A2 US 9202043 W US9202043 W US 9202043W WO 9216181 A2 WO9216181 A2 WO 9216181A2
Authority
WO
WIPO (PCT)
Prior art keywords
pdgf
dexamethasone
tissue
regeneration
composition
Prior art date
Application number
PCT/US1992/002043
Other languages
English (en)
Other versions
WO1992016181A3 (fr
Inventor
Robert Bruce Rutherford
Marc F. Charette
Original Assignee
Creative Biomolecules, Inc.
University Of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules, Inc., University Of Connecticut filed Critical Creative Biomolecules, Inc.
Priority to AT92908042T priority Critical patent/ATE196604T1/de
Priority to AU15591/92A priority patent/AU656372B2/en
Priority to EP92908042A priority patent/EP0575484B1/fr
Priority to CA002106073A priority patent/CA2106073C/fr
Priority to DE69231486T priority patent/DE69231486T2/de
Priority to JP4507585A priority patent/JPH07505858A/ja
Publication of WO1992016181A2 publication Critical patent/WO1992016181A2/fr
Publication of WO1992016181A3 publication Critical patent/WO1992016181A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Polypeptide growth factors are a class of natural biological mediators that regulate the proliferation, differentiation, motility and matrix synthesis of nearly all cell types. These properties, demonstrable in vivo, have led to the proposal that such factors play important roles in soft and hard tissue repair.
  • Platelet-derived growth factor (PDGF) is a well characterized example of such a polypeptide growth factor.
  • PDGF is a peptide hormone produced by blood platelets which influences the regulation of a broad array of biological systems including wound repair, arteriosclerosis, neoplasia, embryogenesis and bone marrow fibrosis.
  • PDGF is a mitogen, that is, a substance which induces mitosis of cells and thus cellular proliferation.
  • PDGF elicits both chemotactic and mitogenic responses in fibroblasts, smooth muscle, glial cells, etc.
  • Injury to the endothelium lining the vessel wall is believed to cause platelets to adhere to exposed connective tissue at the wound site, with the concomitant release of PDGF.
  • the released PDGF is thought to chemotactically recruit many cell types including fibroblasts, monocytes, glial and smooth muscle to migrate into the site of the wound. Increased proliferation of these cells leads to accelerated tissue regeneration and wound healing.
  • dexamethasone acts synergistically with cartilage-derived growth factor (CDGF) to enhance the stimulation of DNA synthesis in quiescent Swiss 3T3 cells, while having only a neutral effect with PDGF.
  • CDGF cartilage-derived growth factor
  • Levenson et al. showed that the addition of dexamethasone to PDGF-stimulated cultures had no effect on DNA synthesis over that observed with PDGF alone.
  • the present invention relates to a method for enhancing tissue regeneration and/or wound repair in a mammal comprising applying to the tissue or wound an effective amount of a composition comprising an anti- inflammatory compound and PDGF.
  • the method promotes cellular activity at the site of the wound which expedites healing of the wound.
  • the combination of PDGF and anti-inflammatory compound synergistically promotes the proliferation of mammalian cells at the site.
  • Either natural-sourced or recombinant PDGF can be used in the composition.
  • many anti- inflammatory agents can synergistically enhance the mitogenic effect of PDGF on cells.
  • Anti-inflammatory agents which are particularly useful are a class of compounds known as glucocorticoids. Glucocorticoids include cortisone, hydrocortisone (cortisol), dexamethasone, and pharmacologically active derivatives thereof, for example.
  • the method of the present invention can be used to promote tissue regeneration and/or wound healing in a variety of tissues.
  • the method is effective for enhancing tissue regeneration and wound healing in epithelial tissues, and for promoting regeneration of bone and/or cartilage tissues.
  • applying the composition to an area where epithelium, bone or cartilage has been broken, torn or eroded due to injury or disease for example, stimulates the regeneration and repair of the epithelium, bone or cartilage.
  • the method is particularly effective for treating tissues affected by periodontal disease.
  • the method is carried out by applying a composition of PDGF and the anti-inflammatory compound to the affected gum tissue and periodontal ligament.
  • the composition promotes regeneration of the gum tissue, of tooth tissues such as dentin and pulp, and of the connective tissue holding the tooth in place in the gum.
  • the present method provides an effective therapeutic composition for treating external wounds, including skin ulcers, burns and lesions and for regenerating connective tissue and/or bone.
  • the method is particularly effective for treating dental tissue affected by periodontal disease.
  • Figure 1 is a graph showing the influence of dexamethasone on the mitogenic activity of both PDGF alone and PDGF + IGF-1.
  • Figure 2 is a graph showing the effect on cell population density of various concentrations of dexamethasone an PDGF + IGF-1.
  • Figure 3 is a graph showing the influence of dexamethasone on the mitogenic activity of PDGF using PDGF + IGF-1 as control reference.
  • Figure 4 is a graph comparing the mitogenic activity of PDGF- ⁇ and PDGF- ⁇ .
  • the present method comprises applying a combination of PDGF and an anti-inflammatory compound to a tissue.
  • Native PDGF is a dimeric molecule comprised of two polypeptide chains, one or more of which may be glycosylated.
  • the two chains (referred to as alpha ( ⁇ ), and beta ( ⁇ )) are homologous but not identical.
  • the ⁇ chain has a molecular weight of about 17,000 to 18,000 and the ⁇ chain has a molecular weight of about 13,000 to 14,000.
  • the ⁇ and ⁇ chains are synthesized in vivo from larger molecules which are subsequently processed at the amino and carboxyl- termini.
  • the mature human ⁇ chain is comprised of 110 or 125 amino acids and various N-linked sugar side chains, and the length and amino acid sequence is dependent on the tissue source.
  • the fully processed human ⁇ chain is encoded by the c-sis gene and is comprised of 112 amino acids.
  • Biologically active PDGF can exist as a homodimer e.g., ⁇ , ⁇ , or a heterodiminer ⁇ .
  • the molecular weights of the ⁇ homodimer and ⁇ homodimer are about 35,000 and about 32,000, respectively.
  • PDGF useful in the present invention may be natural sourced, recombinant or synthetic PDGF.
  • Natural sourced can be extracted from human platelets, for example as described by Popen et al. (1979) Proc. Natl. Acad. Sci. USA, 7_6_:3722-33726; Antoniades et al. (1979) Proc. Natl. Acad. Sci. USA, 7_6:1809-1813, Antoniades et al., U.S. Patent No. 4,479,896; and Lipton et al. ; U.S. Patent No. 4,350,687.
  • Recombinant PDGF can be produced using transformed eucaryotic cells, such as yeast, (See, EP Publication No.
  • PDGF also can be synthesized using art-recognized peptide synthesis techniques. Biologically active fragments. derivatives or mutant forms of PDGF can be used in the present invention.
  • PDGF which can be used is commercially available, for example, from Amgen Corporation, Thousand Oaks, California; PDGF Inc., Boston, Massachusetts; Collaborative Research Inc., Waltham, Massachusetts; and Creative BioMolecules, Inc., Hopkinton, Massachusetts.
  • Anti-inflammatory compounds are compounds which reduce inflammation by acting on body mechanics without directly antagonizing the causative agent.
  • a class of anti-inflammatory compounds which is particularly useful in the present method comprises glucocorticoids.
  • Glucocorticoids include, for example, cortisone, hydrocortisone (cortisol), dexamethasone and pharmacologically active derivatives of these drugs, e.g., hydrocortisone acetate.
  • Dexamethasone and cortisol are commercially available from a number of sources, for example, Sigma Chemical Co., Saint Louis, Missouri. Wound healing and tissue regeneration can be promoted by directly, locally applying an effective amount of a composition comprising PDGF and the selected anti-inflammatory compound to the affected tissue.
  • the tissue can be external epithelial tissue, internal epithelial tissue, bone, cartilage, or dental tissue, including gum tissue, dentin, pulp, ceraentum or periodontal ligature.
  • the concentration of PDGF and of the anti- inflammatory compound will depend in part upon the compound selected, its potency and the tissue it is applied to. The amount can be determined empirically by applying a low dose and observing the effects and incrementally increasing the dose until the desired effect is obtained.
  • a concentration of PDGF of from about 0.1 ⁇ g/ml to about 10 mg/ml is effective for most applications.
  • a concentration of from about 10 " 5 M to about 10 " 12 M can be used.
  • a concentration of from about 10 " 5 M to about 10 "12 M of dexamethasone has been shown to significantly enhance the activity to PDGF.
  • a concentration of about 10 "5 to about 10 " 9 M is most preferred.
  • TGF- ⁇ transforming growth factor- ⁇
  • IGF-1 insulin-like growth factors
  • IGF-1 or other growth factor can be added to the PDGF mixture in a weight-to-weight ratio, for example, of about 1:4 and 25:1, preferably between about 1:2 and 10:1, and more preferably 1:1 or 2:1.
  • a pharmaceutically acceptable carrier substance for local, topical administration.
  • pharmaceutically acceptable carriers include, for example, commercially available inert gels, or liquids supplemented with albumin, methyl cellulose or a collagen matrix. Typical of such formulations are ointments, creams and gels.
  • Ointments are typically prepared using an oleaginous base, e.g., containing fixed oils or hydrocarbons, such as white petrolatum or mineral oil, or an absorbent base, e.g., consisting of an absorbent anhydrous substance or substances, for example, anhydrous lanolin. Following formation of the base, the active ingredients are added in the desired concentration.
  • Creams generally comprise an oil phase (internal phase) containing typically fixed oils, hydrocarbons, and the like, such as waxes, petrolatum, mineral oil, and the like, and an aqueous phase (continuous phase), comprising water and any water-soluble substances, such as added salts.
  • an emulsifying agent for example, a surface active agent, such as sodium laurul sulfate; hydrophilic colloids, such as acacia colloidal clays, beegum, and the like.
  • a surface active agent such as sodium laurul sulfate
  • hydrophilic colloids such as acacia colloidal clays, beegum, and the like.
  • the active ingredients are added in the desired concentration.
  • Gels are comprised of a base selected from an oleaginous base, water, or an emulsion-suspension base, as previously described.
  • a gelling agent which forms a matrix in the base, increasing its viscosity to a semisolid consistency. Examples of gelling agents are hydroxypropyl cellulose, acrylic acid polymers, and the like.
  • the active ingredients are added to the formulation at the desired concentration at a point preceding addition of the gelling agent.
  • a typical gel formulation useful for the topical administration of PDGF and dexamethasone comprises the following: % by Weight sterile distilled water 92.38 sodium dibasic phosphate 0.03 CarbapolTM 0.5 glycerin 1.6 m-cresol 0.25 sodium hydroxide (IN) 0.5
  • a bone collagen matrix as described in U.S. Patent No. 4,975,526, which is incorporated herein by reference, can be used as the carrier for application to bone and/or cartilage.
  • the collagen matrix described in this patent is a biodegradable, biocompatible, mineral-free, insoluble Type-I bone collagen particles being depleted of non-collagenous protein.
  • the collagen matrix particles have a mean diameter of about 70 ⁇ m - 850 ⁇ m, and an increased intraparticle surface area relative to untreated material.
  • PDGF and the anti- inflammatory agent are first dissolved in a suitable solvent such as buffered sterile saline and then added to the collagen matrix. The mixture is vortexed, and the matrix is lyophilized and shaped as desired or implanted into an area of bone or cartilage by packing.
  • matrix materials include synthetic homopolymers and copolymers of glycolic acid and lactic acid, hydr ⁇ xyapatite, tricalcium and other calcium phosphates, and particulate demineralized guanidine extracted species-specific (allogenic) bone.
  • the matrix containing the PDGF and steroid can be applied into a shape spanning the bone or cartilage defect to serve as a "temporary scaffold" and substratum as a base for anchoring and proliferation of differentiated tissue cells.
  • the method is particularly useful for treating tissues affected by periodontal disease.
  • Periodontal disease is characterized by gingivitis, destruction of alveolar bone and periodontal ligament, apical migration of the epithelial attachment resulting in the formation of periodontal pockets.
  • a number of different tissues are involved, including epithelium, cartilage and bone.
  • the method of the invention promotes healing and regeneration of the gum tissues (epithial tissue) the periodontal ligament (cartilage) and the jaw bone (bone). Pulp and dentin tissue within the tooth which was eroded or attacked by periodontal disease can be regenerated using the present method.
  • the most preferred composition for this purpose is a combination of PDGF and dexamethasone.
  • PDGF mitogenesis is enhanced in the presence of a glucocorticoid.
  • Current methodologies described in the literature disclose the use of PDGF as an agent to enhance tissue repair or reduce regeneration jln vivo utilizing another human growth factor, IGF-1 in combination with PDGF. This is substantially more expensive and less effective than using the small amounts (e.g., less than 10 " 5 M) of glucocorticoid drugs, as described herein.
  • the glucocorticoids have anti-inflammatory properties, which are beneficial where inflammation is present, such as with many periodontal diseases.
  • glucocorticoid drug in a preferred concentration of from about 10 " 7 M to about 10 " 9 M was consistently more effective than adding l ⁇ g/ml IFG-1 for enhancing the cell proliferation which is the basis of tissue regeneration and repair.
  • Example 1 Potentiation of mitogenic effect of PDGF and IGF-1 by Dexamethasone
  • the following experiments were all performed on low passage, human diploid fibroblasts obtained from the periodontal ligaments and dental pulps of extracted teeth.
  • the cells were cultured under standard culture conditions and stocks were propagated with 10% fetal bovine serum (FBS) as the source of growth factors.
  • FBS fetal bovine serum
  • the cells were plated at 10,000 to 15,000 cells per 1.88 cm 2 of surface area in 24 well culture plates and conditioned in medium containing 0.1% FBS for 24-48 hours prior to treatment. The cells were then exposed once to the indicated concentrations of PDGF, IGF-1 and/or dexamethasone in culture media at time zero.
  • the cells were quantitatively harvested from each well and the total cell population densities were determined using a Coulter counter by standard methods.
  • the PDGF- ⁇ and PDGF- ⁇ used in these studies were recombinant human analogs of PDGF produced in E_. coli which were provided by Creative BioMolecules, Hopkinton, Massachusetts.
  • the dexamethasone was purchased from Sigma Chemical Company, St. Louis, Missouri.
  • Plate 3 contained PDGF- ⁇ 200 ng/ l + 1GF-1 200 ng/ml
  • Plate 4 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 " M Dexamethasone
  • Plate 5 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 " M Dexamethasone
  • Plate 8 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 "10 M Dexamethasone
  • Plate 9 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 _11 M Dexamethasone
  • Plate 10 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 "12 M Dexamethasone
  • Plate 11 contained PDGF- ⁇ 200 ng/ml + 10 " 7 M Dexamethasone Plate 12 contained PDGF- ⁇ 200 ng/ml
  • Figure 1 shows that cultures treated with dexamethasone in combination with PDGF proliferated faster than cultures treated with PDGF alone and PDGF + IGF-1.
  • Figure 2 shows that dexamethasone is effective in enhancing all proliferation over concentrations ranging from 10 " 5 to 10 _11 M.
  • the concentration of dexamethasone to optimally potentiate the mitogenic activity of PDGF at 200 ng/ml is about 10 " 7 M.
  • the mitogenic activity of the cells was increased by the combination of dexamethasone and PDGF more than by just PDGF alone or PDGF + IGF-1. However, there was no further enhancement of mitogenic activities by the addition of IGF-1 to PDGF and dexamethasone.
  • Example 2 Comparison of the effects on mitogenic activity of dexamethasone with IGF-1 over time. To determine the time course of the effects of dexamethasone on PDGF- ⁇ mitogenic activity, cultures were treated with PDGF + IGF-1 and PDGF with and without dexamethasone at 10 " 7 and 10 "12 M, harvested and counted at the time indicated over a period of 160 hours. Data from the same experiment are plotted against the controls in two separate plots for clarity. The results, shown in Figure 3, revealed that a single exposure of the cultured cells at time zero to PDGF- ⁇ plus dexamethasone resulted in final increased cell population densities after 160 hours that were similar to those obtained by exposure of the cultured cells to PDGF- ⁇ plus IGF-1.
  • the final total cell number was similar for treatment with 10 ng/ml and 500 ng/ml PDGF- ⁇ .
  • the PDGF- ⁇ + IGF-1 treated cultures reached maximal cell population densities at 96 hours, while those exposed to PDGF- ⁇ + dexamethasone had not plateaued by 160 hours, demonstrating the prolonged effect of a single dose of PDGF + dexamethasone on cell proliferation.
  • Example 3 Comparison of the Mitogenic Activity of PDGF- ⁇ and PDGF- ⁇ .
  • Plates prepared as described above were treated with PDGF- ⁇ or PDGF- ⁇ and dexamethasone or IGF-1. The extent of cell growth determined.
  • Plate 1 contained 0.1% FBS + 10 " 7 M dexamethasone.
  • Plate 2 contained PDGF- ⁇ 500 ng/ml.
  • Plate 3 contained PDGF- ⁇ 500 ng/ml + IGF-1 500 ng/ml.
  • Plate 4 contained PDGF- ⁇ 500 ng/ml + 10 " 5 M dexamethasone.
  • PDGF- ⁇ Studies 5 contained 0.1% FBS _ 10 " 7 dexamethasone.
  • Plate 6 contained PDGF- ⁇ 500 ng/ml.
  • Plate 7 contained PDGF- ⁇ 500 ng/ml + IGF-1 500 ng/ml.
  • P PIlate 8 contained PDGF- ⁇ 500 ng/ml + 10 " 7 M dexamethasone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédé de régénération tissulaire, de traitement des lésions externes et de traitement de la maladie desmodontale. Il consiste à appliquer sur le tissu atteint une quantité efficace d'une composition constituée du facteur mitogénique plaquettaire (PDGF) et d'un composé anti-inflammatoire. La présence de ce dernier renforce l'activité du PDGF dans la stimulation de la croissance cellulaire, ce qui favorise la régénération tissulaire et/ou la cicatrisation.
PCT/US1992/002043 1991-03-12 1992-03-12 Procede favorisant la reparation et la regeneration tissulaires WO1992016181A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT92908042T ATE196604T1 (de) 1991-03-12 1992-03-12 Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und - regenerierung
AU15591/92A AU656372B2 (en) 1991-03-12 1992-03-12 Composition for promoting tissue repair and regeneration
EP92908042A EP0575484B1 (fr) 1991-03-12 1992-03-12 Composition comprenant pdgf et dexamethasone pour favoriser la reparation et la regeneration des tissus
CA002106073A CA2106073C (fr) 1991-03-12 1992-03-12 Composition stimulant la reparation et la regeneration tissulaires
DE69231486T DE69231486T2 (de) 1991-03-12 1992-03-12 Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und -regenerierung
JP4507585A JPH07505858A (ja) 1991-03-12 1992-03-12 組織の修復および再生促進方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/669,070 US5149691A (en) 1991-03-12 1991-03-12 Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
US669,070 1991-03-12

Publications (2)

Publication Number Publication Date
WO1992016181A2 true WO1992016181A2 (fr) 1992-10-01
WO1992016181A3 WO1992016181A3 (fr) 1992-11-12

Family

ID=24684879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002043 WO1992016181A2 (fr) 1991-03-12 1992-03-12 Procede favorisant la reparation et la regeneration tissulaires

Country Status (8)

Country Link
US (2) US5149691A (fr)
EP (1) EP0575484B1 (fr)
JP (1) JPH07505858A (fr)
AT (1) ATE196604T1 (fr)
AU (1) AU656372B2 (fr)
CA (1) CA2106073C (fr)
DE (1) DE69231486T2 (fr)
WO (1) WO1992016181A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045533A1 (fr) * 1996-05-28 1997-12-04 The Regents Of The University Of Michigan Reconstitution de tissus buccaux
WO2003037356A1 (fr) * 2001-10-26 2003-05-08 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique contenant un facteur de croissance et/ou une cytokine et un biguanide antiseptique
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7847087B2 (en) 2001-03-05 2010-12-07 Siemens Healthcare Diagnostics Inc. Methods and primers for evaluating HIV-1 mutations
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US9642891B2 (en) 2006-06-30 2017-05-09 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US10258566B2 (en) 2004-10-14 2019-04-16 Biomimetic Therapeutics, Llc Compositions and methods for treating bone
US11235030B2 (en) 2010-02-22 2022-02-01 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149691A (en) * 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5444151A (en) * 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
US5326695A (en) * 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE69418865T2 (de) * 1993-03-29 2000-02-17 Zymogenetics, Inc. Osteoblastswachstumfordernde zusammensetzungen die pdgf und vitamin-d enthalten
US5455041A (en) * 1993-09-13 1995-10-03 Research Foundation Of State University Of New York At Buffalo Method for inducing periodontal tissue regeneration
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
EP0743066A3 (fr) * 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Agent cicatrisant
US5776193A (en) * 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
US6902584B2 (en) 1995-10-16 2005-06-07 Depuy Spine, Inc. Bone grafting matrix
DE19754140A1 (de) * 1997-12-05 1999-06-24 Era Beschichtung Gmbh & Co Kg Innenraummaterial auf der Basis von Kunststoff, Verfahren zu dessen Herstellung und Verwendung desselben
MXPA00000009A (es) 1998-06-22 2005-09-08 Autologous Wound Therapy Inc Solicitud para patente de utilidad para curativo de heridas mejorado enriquecido con plaquetas.
WO2001032197A2 (fr) * 1999-11-02 2001-05-10 Eli Lilly And Company Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques
KR20050007585A (ko) * 2001-06-07 2005-01-19 치오우 컨설팅, 인코포레이티드 아프타 궤양 및 단순 헤르페스 병변의 예방 및 치료조성물 및 방법
US7819888B2 (en) * 2001-10-23 2010-10-26 Innovasive Devices, Inc. Method and apparatus for harvesting and implanting bone plugs
CN1668317B (zh) 2002-05-09 2010-04-28 医学基因公司 用于处理伤口的含血浆或血清的药物组合物
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
US6616923B1 (en) * 2002-07-26 2003-09-09 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
US20060076295A1 (en) 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
ATE510605T1 (de) 2003-03-14 2011-06-15 Univ Columbia Systeme und verfahren für auf blut basierende therapien mit einer membranlosen mikrofluid- austauschvorrichtung
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US7258875B2 (en) * 2003-12-04 2007-08-21 Chiou Consulting, Inc. Compositions and methods for topical treatment of skin infection
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
GB0414803D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Composition
US20060115266A1 (en) * 2004-12-01 2006-06-01 Gil Levi All-optical protection signaling systems and methods in optical communication networks
WO2007016620A2 (fr) 2005-08-01 2007-02-08 Genera Doo Methodes et compositions de regeneration de cartilage articulaire
BRPI0618794A2 (pt) 2005-11-17 2011-09-13 Biomimetic Therapeutics Inc uso de uma matriz biocompatìvel, kit e composição para aumento ósseo, especialmente para aumento do osso maxilofacial
KR101020658B1 (ko) 2006-01-23 2011-03-09 주식회사 이매진 신규한 펩타이드 및 이의 용도
ATE542583T1 (de) 2006-05-22 2012-02-15 Univ Columbia Verfahren für membranlosen mikrofluidaustausch in einem h-filter und filterung der extraktionsflüssigkeitsausgangsströme
AU2013203287B2 (en) * 2006-11-03 2015-12-17 Biomimetic Therapeutics, Llc. Compositions and methods for arthrodetic procedures
AU2007333425B2 (en) 2006-11-03 2014-03-27 Biomimetic Therapeutics, Llc Compositions and methods for arthrodetic procedures
US9511076B2 (en) * 2008-05-30 2016-12-06 Clarion Research Group Formulations and methods for recovery from dental surgery
WO2009052221A2 (fr) * 2007-10-15 2009-04-23 The Regents Of The University Of Colorado Procédés d'extraction de plaquettes et compositions obtenues à partir de ceux-ci
CA3162567A1 (fr) 2008-01-07 2009-07-16 Rapid Pathogen Screening, Inc. Utilisation de peptides pour promouvoir la guerison des plaies
CA2714594A1 (fr) 2008-02-04 2009-08-13 Edward F. Leonard Dispositifs de separation de fluide, systemes et procedes
RU2010137106A (ru) 2008-02-07 2012-03-20 Байомайметик Терапьютикс, Инк. (Us) Композиции и способы для дистракциионного остеогенеза
JP5839467B2 (ja) * 2009-03-06 2016-01-06 ユニベルシテ パリ デカルト 癌を治療するための方法
US20130157949A1 (en) 2010-06-14 2013-06-20 Gene Signal International Sa Novel Peptides for Wound Healing
US8288334B2 (en) 2010-06-14 2012-10-16 Gene Signal International Sa Peptides for wound healing
ES2410804T3 (es) 2010-06-14 2013-07-03 Gene Signal International Sa Péptidos para la curación de heridas
EA030418B1 (ru) 2010-07-12 2018-08-31 ЭйТИР ФАРМА, ИНК. ТЕРАПЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ, ПОЛИПЕПТИД АМИНОАЦИЛ-тРНК-СИНТЕТАЗЫ (AARS)
US20130108683A1 (en) * 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating partial and full thickness wounds and injuries
MX356107B (es) 2012-02-16 2018-05-15 Atyr Pharma Inc Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
AU2015332556B2 (en) 2014-10-14 2021-04-29 Samuel Lynch Compositions for treating wounds
AU2018256435B2 (en) 2017-04-20 2025-03-13 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
KR102668789B1 (ko) 2018-11-23 2024-05-24 (주)메디코스바이오텍 창상치료용 약학조성물
CZ308845B6 (cs) 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran
PL245202B1 (pl) 2020-03-06 2024-06-03 Gdanski Univ Medyczny Lipopeptydowe koniugaty i ich sole, sposób wytwarzania lipopeptydowych koniugatów i ich soli, kompozycja farmaceutyczna zawierająca lipopeptydowy koniugat i jego sole do leczenia ran przewlekłych

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4957742A (en) * 1984-11-29 1990-09-18 Regents Of The University Of Minnesota Method for promoting hair growth
US5124316A (en) * 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
CA1322714C (fr) * 1986-11-14 1993-10-05 Harry N. Antoniades Cicatrisation et regeneration osseuse
EP0292517B1 (fr) * 1986-12-11 1992-09-09 Btg International Limited Ameliorations apportees a l'utilisation d'un facteur de croissance epidermique
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
AU657472B2 (en) * 1990-03-06 1995-03-16 Claude Paul Genero Towel or blanket support device
US5149691A (en) * 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
DE69226525T2 (de) * 1991-04-12 1999-04-08 Brigham And Women's Hospital, Boston, Mass. Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885829A (en) * 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues
WO1997045533A1 (fr) * 1996-05-28 1997-12-04 The Regents Of The University Of Michigan Reconstitution de tissus buccaux
US7847087B2 (en) 2001-03-05 2010-12-07 Siemens Healthcare Diagnostics Inc. Methods and primers for evaluating HIV-1 mutations
WO2003037356A1 (fr) * 2001-10-26 2003-05-08 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique contenant un facteur de croissance et/ou une cytokine et un biguanide antiseptique
US11318230B2 (en) 2004-10-14 2022-05-03 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US11571497B2 (en) 2004-10-14 2023-02-07 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US11364325B2 (en) 2004-10-14 2022-06-21 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US9545377B2 (en) 2004-10-14 2017-01-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US10258566B2 (en) 2004-10-14 2019-04-16 Biomimetic Therapeutics, Llc Compositions and methods for treating bone
US9642891B2 (en) 2006-06-30 2017-05-09 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US11058801B2 (en) 2006-06-30 2021-07-13 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US10456450B2 (en) 2006-06-30 2019-10-29 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US11135341B2 (en) 2008-09-09 2021-10-05 Biomimetic Therapeutics, Llc Platelet-derived growth factor composition and methods for the treatment of tendon and ligament injuries
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US11235030B2 (en) 2010-02-22 2022-02-01 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies

Also Published As

Publication number Publication date
CA2106073C (fr) 2003-09-30
WO1992016181A3 (fr) 1992-11-12
DE69231486T2 (de) 2001-04-26
JPH07505858A (ja) 1995-06-29
DE69231486D1 (de) 2000-11-02
AU656372B2 (en) 1995-02-02
CA2106073A1 (fr) 1993-09-13
AU1559192A (en) 1992-10-21
EP0575484A1 (fr) 1993-12-29
ATE196604T1 (de) 2000-10-15
US5149691A (en) 1992-09-22
US5376636A (en) 1994-12-27
EP0575484B1 (fr) 2000-09-27

Similar Documents

Publication Publication Date Title
AU656372B2 (en) Composition for promoting tissue repair and regeneration
US6287606B1 (en) Methods of enhancing wound healing and tissue repair
CA2105997A1 (fr) Methode d'inhibition d'interactions par l'intermediaire d'un ligand padgem, grace a un inhibiteur renfermant de l'acide sialique avec une liaison 2,6
DE69403439T2 (de) Tgf-beta zusammensetzung zum herbeiführen von knochenwachstum
Oates et al. Mitogenic effects of growth factors on human periodontal ligament cells in vitro
GLOBUS et al. Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factorβ
DE69118535T2 (de) Osteo-induktive pharmazeutische formulierungen
US6649168B2 (en) Pharmaceutical compositions comprising TGF-beta
RU2140282C1 (ru) Композиция, стимулирующая рост остеобластов, содержащая фрпт и витамин d
JPH01121300A (ja) 乳汁に由来するポリペプチド成長因子
JP2001506635A (ja) 骨の成長を刺激する組成物および方法
IL182480A (en) Growth factor preparations derived from blood platelets and methods for their use
US8513191B2 (en) Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases
Saito et al. Bone‐resorbing activity and prostaglandin E produced by human periodontal ligament cells in vitro
AU3571389A (en) Pharmaceutical composition containing deoxyribonucleosides and/or deoxyribonucleotides for wound healing
Gamal et al. The effect of local delivery of PDGF‐BB on attachment of human periodontal ligament fibroblasts to periodontitis‐affected root surfaces–in vitro
JP3395904B2 (ja) 創傷治癒および組織修復を高める方法
EP1498135B1 (fr) Preparation pharmaceutique dentaire visqueuse contenant un facteur de croissance des fibroblastes
EP1952821B1 (fr) Agent therapeutique pour la regeneration du complexe dentine-pulpe dentaire
JPH03502922A (ja) インターロイキン‐１蛋白質を含む局所創傷治療用製剤
JPH07504160A (ja) 骨の再生
Mailhot et al. Porous Polysulfone Coated With Platelet‐Derived Growth Factor‐BB Stimulates Proliferation of Human Periodontal Ligament Fibroblasts
JPH07316066A (ja) 創傷治癒剤
US5246700A (en) Pharmaceutical compositions for treating bone disorders
Ksander et al. Exogenous transforming growth factor‐β2 enhances connective tissue formation in transforming growth factor‐β1—deficient, healing‐impaired dermal wounds in mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2106073

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992908042

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992908042

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992908042

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载